SPINE
RhBMP-2/ACS: Cost effective alternative to ICBG in posterolateral lumbar spinal fusion
This report has been verified
by one or more authors of the
original publication.
Spine J. 2008 May-Jun;8(3):443-8. Epub 2007 May 15.
102 patients, over 60 years old, scheduled to undergo an instrumented posterolateral lumbar spine fusion were randomized to receive recombinant bone morphogenetic protein rhBMP-2/ACS or Iliac crest bone graft (ICBG) during the procedure. The use of BMP is a significant cost burden to the patient and hospital. However, upon meticulous calculation of the aggregate cost in the 3 month period after surgery, it was observed that with the utilization of rhBMP, a net savings of $3367 was calculated, primarily due to reduced expenditure on inpatient rehabilitation, decreased hospital reimbursement, physician costs and other outpatient services rendered.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
